Peers for comparison


Market capitalization
‪6.83 B‬ EURMid cap
−2.5 EUR
‪−167.34 M‬ EUR
‪161.56 M‬ EUR
‪66.13 M‬
Beta (1Y)
0.08
Last report date
—
Report period
—
EPS
—
Revenue
—
Earnings release details

Q3 sales reached $92.1M, driven by U.S. acquired HO demand, while Japan launched and European access advanced. Bivamelagon Phase III plans and a royalty buy-down were backed by new term financing.

Employees (FY)
414
Change (1Y)
+131+46.29%
Revenue / Employee (1Y)
‪390.25 K‬ EUR
Net income / Employee (1Y)
‪−404.20 K‬ EUR

Company info


CEO
David P. Meeker
Headquarters
Boston
Founded
2008
IPO date
Oct 5, 2017
ISIN
US76243J1051
CUSIP
76243J105
FIGI
BBG00HY3NMB2
Identifiers
ISIN US76243J1051
CFI code
ESVUFR
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
Summarizing what the indicators are suggesting.
Neutral
Neutral
Neutral
An aggregate view of professional's ratings.
Neutral
Neutral
Neutral
Displays a symbol's price movements over previous years to identify recurring trends.
Weight0.01%
Market value‪208.38 M‬
Weight0.22%
Market value‪171.18 M‬
Weight0.08%
Market value‪147.48 M‬
Weight1.29%
Market value‪128.67 M‬
Weight0.19%
Market value‪82.18 M‬
Weight0.07%
Market value‪66.55 M‬
Weight0.45%
Market value‪61.41 M‬
Weight0.51%
Market value‪56.68 M‬
Weight0.16%
Market value‪34.51 M‬
Weight0.18%
Market value‪32.03 M‬
Weight0.23%
Market value‪20.95 M‬

Explore more ETFs 

Frequently asked questions


Rhythm Pharmaceuticals, Inc. is scheduled to release its next earnings report on Mar 3, 2027.

Why it matters:
– Key event: Earnings often drive significant price moves
– Market expectations: Traders watch revenue, EPS, and guidance vs forecasts
– Volatility spike: Price swings can increase before and after the release

How to use it:
– Track upcoming reports in the Earnings Calendar
– Compare actual results with analyst estimates
– Monitor price reaction and volume on Supercharts
1RV stock is 2.79% volatile and has beta coefficient of 0.08.

What it means:
– Volatility: Shows how much the price fluctuates over time
– Beta > 1: More volatile than the market
– Beta < 1: Less volatile, more stable

Important to know:
– Volatility can increase during earnings, news events, or market stress
– Large-cap stocks like 1RV are typically less volatile than smaller companies

Track every detail on Rhythm Pharmaceuticals, Inc. stock chart and check out the list of the most volatile stocks — is Rhythm Pharmaceuticals, Inc. there?
To understand the 1RV stock performance, it's worth checking price changes for various periods to get the full picture:
– 1 day — −1.65%
– 1 week — +9.82%
– 1 month — +12.58%

1RV all-time low was 3.0 EUR (May 19, 2022), and its highest price is 101.0 EUR (Aug 13, 2026). Find more dynamics in the Stock Heatmap and on the Rhythm Pharmaceuticals, Inc. stock chart.
Rhythm Pharmaceuticals, Inc. market capitalization is ‪6.79 B‬, representing the total value of all its outstanding shares (price × shares outstanding).

What it means:
– Market cap is one of the key ways to classify companies (large-cap, mid-cap, etc.)
– It reflects how investors value the company today
– It changes constantly with stock price movements

What to look at next:
– Market cap trends: Rising cap may signal growth and investor confidence; falling cap can reflect risk or downturns
– Price vs shares: Changes can come from Rhythm Pharmaceuticals, Inc. stock price moves or share count (buybacks, issuance)
– Valuation ratios: Compare market cap with revenue and earnings
– Peer comparison: See how Rhythm Pharmaceuticals, Inc. stacks up against other companies
The safest way to buy Rhythm Pharmaceuticals, Inc. stocks is through a reliable broker. Create an account, fund it, and place a buy order.

You can trade 1RV directly from TradingView:
– Choose a broker: Explore our supported trading partners and pick one that fits your needs
– Compare options: View available brokers side by side to evaluate fees and features
– Connect your account: Open Supercharts, click “Trade”, select your broker, and log in
– Start trading: Place orders without leaving the chart

Tip: If you’re new to trading, try paper trading first — it lets you practice strategies in real market conditions without risking funds.
As of Nov 7, 2026, the company has 414 employees.

Why traders follow this data:
– Company scale: Employee count reflects the size and global reach of the business
– Operational footprint: Higher headcount often indicates broader product lines, retail presence, or services
– Trend signal: Changes over time can reflect hiring growth, restructuring, or efficiency improvements

See our rating of the largest employers to find more opportunities.
Investing in Rhythm Pharmaceuticals, Inc. depends on your goals, risk tolerance, and market conditions. It’s essential to analyze the stock before making a decision.

First, study Rhythm Pharmaceuticals, Inc. financials and track their dynamics on the Fundamental Graphs:
– Business fundamentals: Revenue, earnings, and growth trends
– Valuation: P/E ratio, market cap, and how it compares to peers
– Profitability: Margins, return on equity, and cash flow
– Dividends (if any): Yield, payout ratio, and consistency

Then explore our 1RV technicals – signals based on essential indicators calculations:
– Today — buy
– 1-week — buy
– 1-month — buy

Combine fundamental and technical analysis for better results.
Rhythm Pharmaceuticals, Inc. stock ticker depends on the exchange where it’s listed. On the NASDAQ, its primary exchange, Rhythm Pharmaceuticals, Inc. stocks trade under the symbol RYTM.

About tickers:
– Unique identifiers: A ticker is a short code used to find and trade a stock
– Exchange-specific: The same company may have different tickers across exchanges
– Search shortcut: Used on trading platforms, charts, and screeners

Remember:
– Some companies have multiple listings
– Always check the exchange prefix to avoid confusion

Learn how to find your desired assets in our Symbol Search.
1RV earnings for the last quarter are −0.54 EUR per share, whereas the estimation was −0.63 EUR, resulting in a 14.05% surprise. The estimated earnings for the next quarter are −1.99 EUR per share.

How to read financials:
– Compare actual vs estimates: Earnings beats or misses often drive price moves
– Watch market reaction: Price response matters as much as the numbers
– Look at forward guidance: Future estimates signal expected growth
– Track trends: Analyze results across multiple quarters, not just one

Follow other essential metrics in Rhythm Pharmaceuticals, Inc. financials:
– Revenue growth: Shows business expansion
– Margins (operating, net): Reflect profitability and efficiency
– Free cash flow: Indicates real cash generation
– Debt levels: Impacts financial stability and risk
Rhythm Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪81.32 M‬ EUR despite the estimated figure of ‪75.53 M‬ EUR. In the next quarter revenue is expected to reach ‪97.71 M‬ EUR.

How to read this data:
– Compare actual vs estimates: Revenue beats or misses can move the stock
– Watch market reaction: Price response shows how investors interpret results
– Look at growth: Compare with previous quarters and year-over-year data
– Track trends: One quarter matters less than consistent performance

Follow other essential metrics in Rhythm Pharmaceuticals, Inc. financials:
– Earnings (EPS): Profitability per share
– Margins (gross, operating): Efficiency and cost control
– Free cash flow: Cash available after expenses
Yes, you can track Rhythm Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.

Use our Earnings Calendar to never miss important releases and spot opportunities early.
1RV net income for the last quarter is ‪−36.52 M‬ EUR, while the quarter before that showed ‪−43.17 M‬ EUR of net income which accounts for 15.40% change.

How to read this data:
– Track changes: Compare net income across quarters to spot trends
– Watch expectations: Compare with estimates to gauge performance
– Check margins: Net income reflects profitability after all expenses
– Look beyond one quarter: Consistency matters more than a single result

Follow other essential metrics in Rhythm Pharmaceuticals, Inc. financials:
– Revenue: Overall business growth
– Earnings per share: Rising EPS over time often points to improving business performance
– Margins (gross, operating): Efficiency and cost control
No, Rhythm Pharmaceuticals, Inc. does not currently pay dividends to its shareholders.

Instead of distributing profits as cash payments, the company may choose to reinvest earnings back into the business — for example, in growth, innovation, acquisitions, or debt reduction.

What to consider instead:
– Earnings growth: Is the company increasing profitability over time?
– Revenue expansion: Is the business scaling its operations?
– Free cash flow: Does it generate enough cash to potentially support future dividends?
– Share buybacks: Some companies return capital through repurchasing shares instead of dividends
1RV reached its all-time high of 101.0 EUR on Aug 13, 2026. Its all-time low was 3.0 EUR and was reached on May 19, 2022.

Explore the Rhythm Pharmaceuticals, Inc. stock price chart to see more price history, and discover companies reaching new all-time highs and lows.
Rhythm Pharmaceuticals, Inc. EBITDA is ‪−164.39 M‬ EUR, with an EBITDA margin of −100.49%.

EBITDA is a measure of core operating performance, showing how much profit the company generates from its main business activities before accounting for financing and accounting-related costs.

What it means:
– Operating strength: Helps assess profitability from core operations
– Efficiency signal: Rising EBITDA often reflects improving business performance
– Comparability: Useful for comparing companies with different capital structures

What to look at next in Rhythm Pharmaceuticals, Inc. statements:
– Revenue growth: Shows whether the business is expanding
– Net income: Captures full profitability after all expenses
– Free cash flow: Shows actual cash generated
– Debt levels: Important when evaluating earnings quality
Analyst forecasts suggest a price range between 100.09 EUR and 150.13 EUR for 1RV, based on current estimates.

Remember:
– Forecasts show possible scenarios, not guaranteed outcomes
– They're based on multiple analysts’ models and assumptions
– Target prices change with earnings, news, and market conditions

Don't rely on analysts' opinions alone:
– Use technical analysis: Trend, support/resistance, momentum
– Study fundamentals: Revenue, earnings, margins
– Account for market context: News, macro trends, sector performance